Functional clotting assay to monitor low molecular weight heparin dosage

Biren A. Bhatt, David Kristol, Charles R. Spillert

Research output: Contribution to conferencePaper

Abstract

Low molecular weight heparin (LMWH), an anticoagulant drug, has seen increased use in a variety of clinical situations. Mercuric ion (Hg2+) has been shown to increase procoagulant activity via Tissue Factor (TF) stimulated production of Factor Xa, a pathway that has been linked to many thrombotic disorders. The effects of Hg2+ on heparinized blood may provide valuable insight into the effectiveness of LMWH to counteract TF-induced hypercoagulability. We performed in vitro studies by spiking human citrated whole blood (CWB) with HgCl2 and LMWH at final concentrations of 0.01% HgCl2, 0.5 U/mL LMWH, and a combination of these agents. The samples (n=19) were incubated at 37° for 10 minutes and recalcified with 0.1 M CaCl2 to initiate clotting. The clotting or recalcification time (RT) was measured with a Sonoclot Coagulation Analyzer. The results indicate that HgCl2 was able to significantly (p<0.0001) reduce the anticoagulant ability of LMWH. The data warrants a reassessment of current LMWH monitoring and therapeutic protocols.

Original languageEnglish (US)
Pages45-46
Number of pages2
Publication statusPublished - Jan 1 2002
Externally publishedYes
EventIEEE 28th Annual Northeast Bioengineering Conference - Philadelphia, PA, United States
Duration: Apr 20 2002Apr 21 2002

Other

OtherIEEE 28th Annual Northeast Bioengineering Conference
CountryUnited States
CityPhiladelphia, PA
Period4/20/024/21/02

    Fingerprint

All Science Journal Classification (ASJC) codes

  • Bioengineering

Cite this

Bhatt, B. A., Kristol, D., & Spillert, C. R. (2002). Functional clotting assay to monitor low molecular weight heparin dosage. 45-46. Paper presented at IEEE 28th Annual Northeast Bioengineering Conference, Philadelphia, PA, United States.